沙库巴曲缬沙坦联合硝苯地平控释片治疗2型糖尿病肾病合并高血压患者的临床效果

Clinical effect of sacubitril valsartan combined with nifedipine controlled-release tablets in the treatment of patients with type 2 diabetic nephropathy complicated with hypertension

目的 探究沙库巴曲缬沙坦联合硝苯地平控释片对2型糖尿病肾病合并高血压患者的治疗效果。方法 选取2022年1月至2023年1月高州市人民医院收治的2型糖尿病肾病合并高血压患者100例,以随机数表法将其分为两组,对照组给予缬沙坦80 mg qd与硝苯地平控释片30 mg qd降压治疗,观察组给予沙库巴曲缬沙坦200 mg qd与硝苯地平控释片30 mg qd降压治疗,比较两组患者治疗前后血压、血糖、肾功能指标、血管内皮相关因子及炎性因子变化情况,同时观察两组患者不良反应的发生情况。结果 观察组治疗后血压、空腹血糖、糖化血红蛋白低于对照组,差异有统计学意义(P <0.05);观察组治疗后肌酐、尿素氮、尿微量白蛋白、胱抑素C水平低于对照组,差异有统计学意义(P <0.05);观察组治疗后血管紧张素Ⅱ、超敏C反应蛋白、白介素-6水平低于对照组,差异有统计学意义(P <0.05);两组不良反应总发生率比较,差异无统计学意义(P> 0.05)。结论 沙库巴曲缬沙坦联合硝苯地平控释片对于2型糖尿病肾病合并高血压的患者的治疗效果较好,可较好地控制血压和血糖水平,减缓患者肾功能衰竭进程。

Objective To explore the therapeutic effect of combined use of sacubitril-valsartan and nifedipine controlledrelease tablets in patients with type 2 diabetic nephropathy and hypertension.Methods A total of 100 patients with type 2diabetic nephropathy and hypertension admitted to Gaozhou People's Hospital from January 2022 to January 2023 were selected and divided into two groups using the random number table method.The control group was given valsartan 80 mg qd and nifedipine 30 mg qd for antihypertensive treatment.The observation group was given sacubitril valsartan 200 mg qd and nifedipine controlled-release tablets 30 mg qd for antihypertensive treatment.The blood pressure,blood sugar,renal function indicators,and vascular endothelium-related parameters of the two groups of patients before and after treatment were compared.The changes in factors and inflammatory factors were compared,and the occurrence of adverse reactions of patients in the two groups was also examined.Results After treatment,the blood pressure,fasting blood glucose,and glycated hemoglobin in the observation group were lower than those in the control group,with statistically significant differences(P < 0.05).After treatment,the levels of creatinine,urea nitrogen,urinary microalbumin,and cystatin C in the observation group were lower than those in the control group,with statistically significant differences(P < 0.05).The levels of angiotensin Ⅱ,hypersensitive C-reactive protein,and interleukin-6 in the observation group were lower than those in the control group after treatment,with statistically significant differences(P < 0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P > 0.05).Conclusion Sarkubatrivalsartan combined with nifedipine controlled release tablet has a better therapeutic effect on type 2 diabetes nephropathy patients with hypertension,which can better control blood pressure and blood sugar levels and alleviate the process of renal failure in patients.